
Core Insights - iBio, Inc. will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10–12, 2025, in Boston [1] - CEO Martin Brenner will discuss the company's transition to a clinical-stage biotechnology firm and its advancements in the obesity pipeline during a fireside chat on November 10, 2025 [2] - iBio is focused on developing next-generation biopharmaceuticals for various diseases, including obesity, using AI and advanced computational biology [4] Company Developments - The company aims to create a pipeline of innovative antibody treatments to address significant unmet medical needs in cardiometabolic diseases and obesity [4] - iBio's differentiated antibody programs are designed to complement existing obesity therapies and generate long-term value through innovation [2] - CFO Felipe Duran will be available for one-on-one meetings during the conference, indicating a proactive approach to investor engagement [3] Event Participation - The conference will feature a livestream of the event, with a replay available on the investor section of iBio's website [3] - The participation in this conference highlights iBio's commitment to showcasing its advancements and engaging with the investment community [1][2]